Eli Lilly & Co. (LLY) Tops Q3 EPS by 14c

Eli Lilly & Co. (NYSE: LLY) reported Q3 EPS of $0.89, $0.14 better than the analyst estimate of $0.75. Revenue for the quarter came in at $4.96 billion versus the consensus estimate of $4.99 billion.

Eli Lilly & Co. sees FY2015 EPS of $3.40-$3.45, versus prior guidance of $3.20-$3.30 and the consensus of $3.28.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Diana Shipping withdraws bid to acquire Genco Shipping